Tulyp Medical, a Paris-based startup developing a medical device for intelligent pressure-driven perfusion, emerged from stealth and submitted its 510(k) application to the FDA.
Tulyp is led by Mano Iyer, partner at Sofinnova Partners and a serial medtech entrepreneur, who serves as CEO.
"Tulyp's approach is unique because it applies a fundamental physiologic principle to perfusion,” said Iyer in a statement. “By controlling pressure rather than flow, we aim to optimize oxygen delivery, reduce complications, and bring meaningful innovation to vascular procedures. From an investor perspective, Tulyp represents the kind of transformational innovation we seek, with a proven team addressing a significant unmet clinical need, and a clear path to patient impact and commercial success.”
Tulyp's patented technology has been developed by a team of cardiologists, engineers and entrepreneurs to support various procedures that require appropriate oxygenation of tissue that may otherwise be obstructed and lead to severe complications including amputations or death. Tulyp’s approach is based on maintaining the right pressure, which is a key factor in delivering oxygen to the body.
The technology was recently used during a routine leg artery bypass surgery, where it helped stabilize blood pressure and improve oxygenation. Results in the initial procedures demonstrated safety and functionality, with pressure-driven perfusion maintaining stable vascular pressure and improving tissue oxygenation. Tulyp has filed a 510(k) application with the FDA seeking clearance for broad clinical use.
